| |
| |
|
| Insider
Information: |
Higgins John L |
| Relationship: |
Director |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
2,806,928 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$49,374,432 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
2,806,928 |
|
|
| Total
Value |
$49,374,432 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
11
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -34.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2022-12-28 |
417,695 |
2007-02-01 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2024-05-14 |
36,608 |
2013-10-31 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
Director |
2024-01-30 |
2,352,625 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
165 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-08-16 |
4 |
S |
$42.85 |
$428,500 |
D/D |
(10,000) |
110,025 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-10-18 |
4 |
AS |
$55.00 |
$550,000 |
D/D |
(10,000) |
106,581 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2015-06-09 |
4 |
S |
$92.53 |
$928,809 |
D/D |
(10,000) |
126,044 |
0 |
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2018-08-23 |
4 |
OE |
$61.08 |
$610,800 |
D/D |
10,000 |
13,012 |
0 |
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2018-08-23 |
4 |
S |
$187.92 |
$1,879,173 |
D/D |
(10,000) |
3,012 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2022-11-17 |
4 |
AS |
$78.32 |
$783,173 |
D/D |
(10,000) |
416,731 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2022-11-18 |
4 |
OE |
$12.78 |
$127,800 |
D/D |
10,000 |
426,731 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2022-12-16 |
4 |
AS |
$61.87 |
$618,657 |
D/D |
(10,000) |
422,984 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-10-22 |
4 |
OE |
$10.05 |
$169,763 |
D/D |
10,518 |
117,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-03-07 |
4 |
S |
$102.44 |
$1,110,027 |
D/D |
(10,833) |
119,664 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-10-13 |
4 |
OE |
$21.92 |
$249,537 |
D/D |
11,384 |
150,555 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
11,611 |
132,989 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
120,025 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-06-09 |
4 |
OE |
$21.00 |
$252,000 |
D/D |
12,000 |
151,171 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-06-09 |
4 |
AS |
$114.87 |
$1,378,440 |
D/D |
(12,000) |
139,171 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-05-15 |
4 |
OE |
$16.14 |
$200,217 |
D/D |
12,405 |
119,824 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-05-15 |
4 |
AS |
$179.97 |
$2,232,491 |
D/D |
(12,405) |
107,419 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,608 |
286,030 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
12,809 |
138,899 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-08-17 |
4 |
OE |
$14.47 |
$188,009 |
D/D |
12,993 |
101,912 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-08-17 |
4 |
AS |
$243.00 |
$3,157,299 |
D/D |
(12,993) |
88,919 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Director |
– • – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,173 |
2,352,625 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2020-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
13,559 |
210,289 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
13,614 |
156,562 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
13,646 |
129,258 |
0 |
- |
|
165 Records found
|
|
Page 5 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
